A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin s Lymphoma (NHL)

Protocol No
LOXO-BTK-18001
Principal Investigator
Nirav Shah
Phase
I/II
Summary
This research study is being done to test the safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational drug that may treat certain cancers like leukemias and lymphomas, including the one you have been diagnosed with. These cancers are dependent on or “addicted to” a protein made by the cancers called “BTK”. LOXO-305 is a “BTK inhibitor”—it is designed to block both normal and mutated forms of BTK in these cancers, including cancers against which available BTK inhibitors (e.g. ibrutinib, acalabrutinib) have stopped working.
Description
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: